Wedge Capital Management L L P NC Sells 21,403 Shares of Cencora, Inc. $COR

Wedge Capital Management L L P NC lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 19.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 88,409 shares of the company’s stock after selling 21,403 shares during the period. Wedge Capital Management L L P NC’s holdings in Cencora were worth $27,630,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caldwell Trust Co bought a new position in Cencora during the 2nd quarter valued at approximately $46,000. Capital A Wealth Management LLC increased its stake in shares of Cencora by 3,975.0% during the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after buying an additional 159 shares during the period. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in Cencora in the second quarter worth $52,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Barclays assumed coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $373.25.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $341.07 on Friday. The business’s fifty day simple moving average is $346.49 and its two-hundred day simple moving average is $313.16. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54. The company has a market cap of $66.16 billion, a price-to-earnings ratio of 42.90, a P/E/G ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.